BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 29096833)

  • 1. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
    Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
    Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
    Safarova MS; Ezhov MV; Afanasieva OI; Matchin YG; Atanesyan RV; Adamova IY; Utkina EA; Konovalov GA; Pokrovsky SN
    Atheroscler Suppl; 2013 Jan; 14(1):93-9. PubMed ID: 23357149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV; Afanasieva OI; Il'ina LN; Safarova MS; Adamova IY; Matchin YG; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
    Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS; Nissen SE; Nicholls SJ
    Atherosclerosis; 2017 Aug; 263():137-144. PubMed ID: 28641153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
    Ezhov MV; Il'ina LN; Safarova MS; Afanasieva OI; Adamova IY; Atanesyan RV; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2013 Jan; 14(1):101-5. PubMed ID: 23357150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
    Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
    Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
    Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ
    Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):380-8. PubMed ID: 24448227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 survey.
    Stefanutti C; Morozzi C; Di Giacomo S;
    Ther Apher Dial; 2013 Apr; 17(2):169-78. PubMed ID: 23551673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque.
    Ooi EM; Ellis KL; Barrett PHR; Watts GF; Hung J; Beilby JP; Thompson PL; Stobie P; McQuillan BM
    Atherosclerosis; 2018 Aug; 275():232-238. PubMed ID: 29960898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
    Kroon AA; van Asten WN; Stalenhoef AF
    Ann Intern Med; 1996 Dec; 125(12):945-54. PubMed ID: 8967704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL.
    Li C; Chen Q; Zhang M; Liu Y; Chu Y; Meng F; Wang J; Tang J; Luo J; Niu X; Wei M
    BMC Cardiovasc Disord; 2021 Jan; 21(1):41. PubMed ID: 33468066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report.
    Hippe DS; Phan BAP; Sun J; Isquith DA; O'Brien KD; Crouse JR; Anderson T; Huston J; Marcovina SM; Hatsukami TS; Yuan C; Zhao XQ
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):673-678. PubMed ID: 29301785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound.
    Huded CP; Shah NP; Puri R; Nicholls SJ; Wolski K; Nissen SE; Cho L
    J Am Heart Assoc; 2020 Dec; 9(23):e018023. PubMed ID: 33222598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
    Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
    JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia.
    Bos S; Duvekot MH; Touw-Blommesteijn AC; Verhoeven AJ; Mulder MT; Watts GF; Sijbrands EJ; Roeters van Lennep JE
    Atherosclerosis; 2015 Sep; 242(1):226-9. PubMed ID: 26222903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) apheresis.
    Pokrovsky SN; Afanasieva OI; Ezhov MV
    Curr Opin Lipidol; 2016 Aug; 27(4):351-8. PubMed ID: 27213629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.